Key result
Labetalol achieved a significant reduction in blood pressure with relatively few adverse reactions in patients with hypertension.
Observational (n=50)
Hypothesis-generating for dual alpha-beta blockade in hypertension; does not support practice change without randomized trials.
A new alpha- and beta-blocking agent, labetalol, was used to treat 50 hypertensive patients, 34 of them with refractory hypertension. A significant reduction in hypertension was achieved with relatively few adverse reactions. The combination of alpha and beta blockers in labetalol with their mutually opposing characteristics offers an interesting and promising approach to the control of hypertension.
No takes yet. Share an insight, caveat, or question.
Stern et al. (1982) conducted an observational in Hypertension (n=50). Labetalol was evaluated on Reduction in hypertension. Labetalol achieved a significant reduction in blood pressure with relatively few adverse reactions in patients with hypertension.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: